Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-303: Retifanlimab + Carboplatin-Paclitaxel in SCAC
NCT04472429Phase 3Completed
- Sponsor
- Incyte
- Start
- Nov 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of retifanlimab in anal canal squamous cell carcinoma (SCCA), sponsored by Incyte. Started Nov 2020; status: completed.
02
Drugs
retifanlimab
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT04472429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472429.